[6-K] Immutep Limited American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Immutep has filed a Form 6-K to report significant progress in their clinical research program. The filing announces positive updates from the Phase I study of IMP761, marking an important milestone in the development of their first-in-class LAG-3 agonist antibody targeted at treating autoimmune diseases.

Key points from the filing:

• The study focuses on IMP761, a pioneering LAG-3 agonist antibody
• The treatment is specifically designed to address autoimmune diseases
• Phase I results indicate positive developments in the clinical trial
• The filing was signed by CEO Marc Voigt

This development represents a significant step forward in Immutep's immunotherapy pipeline, potentially offering a new therapeutic approach for autoimmune conditions. The company continues to maintain compliance with SEC reporting requirements as a foreign private issuer under Form 20-F.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as June 23, 2025

Commission File Number 001-35428

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐   No ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 23, 2025

IMMUTEP LIMITED
By:		/s/ Marc Voigt
Name:		Marc Voigt
Title:		Chief Executive Officer

FAQ

What type of clinical trial update did IMMP announce in its June 2023 6-K filing?

IMMP announced a positive update from its Phase I study of IMP761, which is a first-in-class LAG-3 agonist antibody being developed for autoimmune diseases.

Who is the current CEO of Immutep Limited (IMMP)?

Marc Voigt is the Chief Executive Officer of Immutep Limited, as evidenced by his signature on the June 23, 2025 6-K filing.

Where is IMMP's principal executive office located?

Immutep Limited's principal executive office is located at Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia.

What SEC forms does IMMP use for its annual reports?

According to the 6-K filing, Immutep Limited (IMMP) files its annual reports using Form 20-F, as indicated by the checked box in the filing.

What was the significant clinical development announced in IMMP's June 2025 6-K?

The 6-K filing announced positive results from the Phase I study of IMP761, which is described as a first-in-class LAG-3 agonist antibody being developed for treating autoimmune diseases.